NASDAQ:OMED OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free OMED Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.89▼$0.8952-Week Range N/AVolume1,201 shsAverage Volume768,904 shsMarket Capitalization$34.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get OncoMed Pharmaceuticals alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About OncoMed Pharmaceuticals Stock (NASDAQ:OMED)OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. OMED Stock News HeadlinesJune 8, 2023 | benzinga.comIonis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, PredictionsApril 7, 2023 | marketwatch.comBispecific Antibody Market Size | Statistics By 2031April 24, 2024 | DTI (Ad)the harsh reality of the stock marketOK, you’re not supposed to say this In fact, maverick investor Graham Lindman says it’s become the silent elephant in the room that everyone is pretending isn’t there. But he just said it: Most stocks suck. And he isn’t saying that figuratively or subjectively… You see, 96% of stocks underperform. Just 4% of “Apex Stocks” generate virtually all the wealth.March 30, 2023 | marketwatch.com2023, Bispecific Antibody Market is thriving worldwide by 2029February 28, 2023 | marketwatch.com2023-2029 Cancer Stem Cell Market Size and Risks Factors Analysis | Survey Report by Absolute ReportsFebruary 27, 2023 | marketwatch.comForecast for 2028, Bispecific Antibody Market 2023, Global Industry Trends, Share, Size, Growth, DemandFebruary 16, 2023 | marketwatch.comBispecific Antibody Market : Top Key Players Data with Upcoming Opportunities and InnovationsFebruary 4, 2023 | marketwatch.comBispecific Antibody Market Insights-Industry changing aspects, New Technologies and Forecast to 2029April 24, 2024 | DTI (Ad)the harsh reality of the stock marketOK, you’re not supposed to say this In fact, maverick investor Graham Lindman says it’s become the silent elephant in the room that everyone is pretending isn’t there. But he just said it: Most stocks suck. And he isn’t saying that figuratively or subjectively… You see, 96% of stocks underperform. Just 4% of “Apex Stocks” generate virtually all the wealth.January 19, 2023 | marketwatch.comBispecific Antibody Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook ReportNovember 18, 2022 | marketwatch.comBispecific Antibody Market New Innovations and Future Expansion 2022-2028 with Top Countries DataNovember 14, 2022 | finance.yahoo.comFallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightSeptember 7, 2022 | au.investing.comImugene welcomes drug development, oncology and cell therapy expert to the teamSeptember 1, 2022 | marketwatch.comShuttle Pharmaceuticals Shares Continue to Surge, Rising 74%August 31, 2022 | marketwatch.comShuttle Pharmaceuticals Shares More Than Triple in DebutAugust 16, 2022 | thestreet.comClosing Bell: Stocks End Higher As Corporate Earnings Take FocusJune 10, 2022 | bizjournals.comBusiness of Pride: When social injustice calls, Nkarta answersMay 25, 2022 | finance.yahoo.comWorldwide Bispecific Antibody Market to 2028 - Ongoing Clinical Trials Assessment by Status, Phase, and RegionMay 24, 2022 | finance.yahoo.comInsights on the Bispecific Antibody Global Market - Approved Drug Sales Forecast Till 2028April 29, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into PanicMarch 10, 2022 | finance.yahoo.comAdenoid Cystic Carcinoma Pipeline is Indicative of Many Opportunities Left For Research and Development, Analyzes DelveInsightFebruary 18, 2022 | uk.finance.yahoo.comUS Cancer Antibodies Market 2028October 15, 2021 | marketwatch.comCowden Syndrome Treatment Market Trending Report 2021| Size, Share, Status and Revenue and Future Predictions to 2027October 6, 2021 | finanznachrichten.deKuick Research: Global Bispecific Antibody Market Forecast Trends Sales Size Insight 2028October 6, 2021 | prnewswire.comGlobal Bispecific Antibody Market Forecast Trends Sales Size Insight 2028July 30, 2021 | finanznachrichten.deAdagio Therapeutics, Inc.: Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of DirectorsJuly 29, 2021 | finance.yahoo.comAdagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of DirectorsSee More Headlines Receive OMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OMED CUSIPN/A CIK1302573 Webwww.oncomed.com Phone650-995-8200FaxN/AEmployees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,100,000.00 Net Margins-18.24% Pretax MarginN/A Return on Equity-13.14% Return on Assets-7.73% Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio5.04 Sales & Book Value Annual Sales$44.42 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / BookN/AMiscellaneous Outstanding Shares38,690,000Free FloatN/AMarket Cap$34.43 million OptionableOptionable Beta1.86 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Perry A. Karsen (Age 64)Exec. Chairman Ms. Jill HenrichSr. VP of Regulatory Affairs & Quality AssuranceDr. Ann Kapoun Ph.D.Sr. VP of Translational MedicineKey CompetitorsFortress BiotechNASDAQ:FBIOViracta TherapeuticsNASDAQ:VIRXVYNE TherapeuticsNASDAQ:VYNEXilio TherapeuticsNASDAQ:XLOCASI PharmaceuticalsNASDAQ:CASIView All Competitors OMED Stock Analysis - Frequently Asked Questions How were OncoMed Pharmaceuticals' earnings last quarter? OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analysts' expectations of $7.97 million. OncoMed Pharmaceuticals had a negative trailing twelve-month return on equity of 13.14% and a negative net margin of 18.24%. What other stocks do shareholders of OncoMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Celldex Therapeutics (CLDX), GW Pharmaceuticals (GWPH), Nightstar Therapeutics (NITE), ImmunoGen (IMGN), Universal Display (OLED), Verastem (VSTM), Alnylam Pharmaceuticals (ALNY) and Clovis Oncology (CLVS). This page (NASDAQ:OMED) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyNew York goes dark, then America.Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoMed Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
